Baseline Characteristics of the ENSEMBLE Study Population: A Phase IIIb Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

被引：0
|
作者：
Carroll, W. [1 ]
Brochet, B. [2 ]
Patti, F. [3 ]
Buffels, R. [4 ]
Wei, W. [4 ]
Vollmer, T. [5 ]
Hartung, H. P. [6 ,7 ]
机构：
[1] Perron Inst, Nedlands, WA, Australia
[2] Ctr Hosp Univ Bordeaux, Bordeaux, France
[3] Univ Catania, Catania, Italy
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA
[6] Heinrich Heine Univ, Dept Neurol, UKD, Ctr Neurol & Neuropsychiat, Dusseldorf, Germany
[7] Heinrich Heine Univ, LVR Klinikum, Dusseldorf, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-76
引用
收藏
页码：475 / 475
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
    Doosti, Rozita
    Moghadasi, Abdorreza Naser
    Azimi, Amir Reza
    Saleh, Shahrokh Karbalai
    Etemadifar, Masoud
    Shaygannejad, Vahid
    Ashtari, Fereshteh
    Harirchian, Mohammad Hossein
    Siroos, Seyed Bahaadin
    Ayramloo, Hormoz
    Majdinasab, Nastaran
    Hojjati, Seyyed Mohammad Masood
    Asghari, Nabiollah
    Baghbanian, Seyed Mohammad
    Cheraghmakani, Hamed
    Abedini, Mahmoud
    Sedighi, Behnaz
    Abadi, Negar Mohseni Abbas
    Ghasemitabar, Maedeh
    Talebianpour, Sara
    Daylari, Tohid Babayi
    Dana, Vahid
    Noie, Neda Ghaleh
    Sahraian, Mohammad Ali
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2021, 12 (03) : 263 - 274
  • [2] Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study
    Bermel, Robert
    Hartung, Hans-Peter
    Brochet, Bruno
    Benedict, Ralph
    Berger, Thomas
    Carroll, William
    Vollmer, Timothy
    Holmoy, Trygve
    Karabudak, Rana
    Killestein, Joep
    Nos, Carlos
    Patti, Francesco
    Ross, Amy Perrin
    Vanopdenbosch, Ludo
    Wuerfel, Jens
    Kuenzel, Thomas
    Kadner, Karen
    Kulyk, Inessa
    Freedman, Mark
    NEUROLOGY, 2023, 100 (17)
  • [3] A phase I, open-label, multicenteir study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS)
    Bar-Or, Amit
    Calabresi, Peter
    Arnold, Douglas
    Markowitz, Clyde
    Shafer, Stuart
    Kasper, Lloyd
    Waubant, Emmanuelle
    Gazda, Suzanne
    Fox, Robert
    Sarkar, Neena
    Panzara, Michael
    Smith, Craig
    NEUROLOGY, 2007, 68 (12) : A84 - A84
  • [4] A prospective, open-label, single-arm clinical trial of the effects of natalizumab on measures of ambulation in relapsing-remitting multiple sclerosis patients: the TIMER study
    Voloshyna, N.
    Nechrych, T.
    You, X.
    Belachew, S.
    Paes, D.
    JOURNAL OF NEUROLOGY, 2013, 260 : S67 - S67
  • [5] Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies
    Vermersch, P.
    Comi, G.
    Siva, A.
    Oreja-Guevara, C.
    Wiendl, H.
    Van Wijmeersch, B.
    Eralinna, J. -P.
    Nicholas, R.
    Buffels, R.
    Bernasconi, C.
    Kuhelj, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 190 - 190
  • [6] Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
    Jai Perumal
    Roumen Balabanov
    Ray Su
    Roger Chang
    Laura Balcer
    Steven Galetta
    Denise I. Campagnolo
    Robin Avila
    Lily Lee
    Danette Rutledge
    Robert J. Fox
    Advances in Therapy, 2021, 38 : 3724 - 3742
  • [7] Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial
    Saida T.
    Kira J.-I.
    Kishida S.
    Yamamura T.
    Ohtsuka N.
    Ling Y.
    Torii S.
    Lucas N.
    Kuesters G.
    Steiner D.
    Tibung J.T.
    Neurology and Therapy, 2017, 6 (1) : 39 - 55
  • [8] Patient-reported SymptoMScreen baseline scores in patients with relapsing-remitting multiple sclerosis enrolled in Phase IIIb studies of ocrelizumab (ENSEMBLE and CASTING)
    Kister, I.
    Hartung, H. P.
    Vermersch, P.
    Buffels, R.
    Kuhelj, R.
    McDougall, F.
    Wei, W.
    Cutter, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 513 - 514
  • [9] Open-label, single-arm, phase 2 study of alemtuzumab in patients with active relapsing-remitting multiple sclerosis who have failed licensed beta-interferon therapies
    Fox, Edward
    Sullivan, Herman
    Gazda, Suzanne K.
    NEUROLOGY, 2007, 68 (12) : A274 - A275
  • [10] Low disability accumulation after 4-year ocrelizumab therapy in treatment-naive patients with early-stage relapsing-remitting multiple sclerosis; data from the Phase IIIb ENSEMBLE study
    Patti, Francesco
    Bermel, Robert
    Brochet, Bruno
    Berger, Thomas
    Carroll, William
    Freedman, Mark S.
    Holmoy, Trygve
    Karabudak, Rana
    Killestein, Joep
    Nos, Carlos
    Vanopdenbosch, Ludo
    Vollmer, Timothy
    Kuenzel, Thomas
    Kadner, Karen
    Kulyk, Inessa
    Hartung, Hans-Peter
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 594 - 596
12345